<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Primary care management of adults with opioid use disorder
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Primary care management of adults with opioid use disorder
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Primary care management of adults with opioid use disorder
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tiffany Lu, MD, MS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Aaron Fox, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melissa Stein, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joann G Elmore, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew J Saxon, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sara Swenson, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 14, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3244514141">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States, opioid use disorder (OUD) has fueled a national crisis of overdose deaths and other opioid-related harms. OUD affects people who use prescription opioids, as well as those who use heroin or other illicit opioids, especially illicitly manufactured
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         . Clinicians encounter people with OUD throughout the health care system, and each point of care can represent an important opportunity to make an OUD diagnosis, offer evidence-based treatment, and connect an individual with ongoing care. Caring for people with OUD is an essential part of primary care, where, as with other chronic health conditions, it can be managed with a long-term treatment plan. This chapter reviews key issues in providing primary care to people with OUD, including the management of common comorbid conditions.
        </p>
        <p>
         Issues related to opioid misuse and OUD in adults are reviewed in detail in other topics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">
          "Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/108803.html" rel="external">
          "Opioid use disorder: Treatment overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">
          "Opioid use disorder: Pharmacologic management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/99647.html" rel="external">
          "Opioid use disorder: Psychosocial management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/121628.html" rel="external">
          "Management of acute pain in adults with opioid use disorder"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4790.html" rel="external">
          "Opioid use disorder: Overview of treatment during pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15236.html" rel="external">
          "Prescription drug misuse: Epidemiology, prevention, identification, and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7808.html" rel="external">
          "Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/99945.html" rel="external">
          "Prevention of lethal opioid overdose in the community"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1257559474">
         <span class="h1">
          DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Person-centered terminology should be used when caring for people with opioid use disorder (OUD). Stigmatizing language (eg, "substance abuser," "addict") perpetuates negative perceptions and attitudes among clinicians and is a commonly cited barrier as to why people with OUD are not engaged in treatment [
         <a href="#rid1">
          1,2
         </a>
         ]. We advise that clinicians use the following terms when evaluating and counseling patients and their supports regarding OUD.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Addiction
         </strong>
         – The American Society of Addiction Medicine defines addiction as a treatable, chronic medical illness involving complex interactions among neural circuits, genetics, the environment, and an individual's life experiences [
         <a href="#rid3">
          3
         </a>
         ]. People with addiction suffer from a problematic pattern of substance use and compulsive behaviors that often continue despite harmful physical and/or psychosocial consequences.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Substance use disorder (SUD)
         </strong>
         – In the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), "substance use disorder" (SUD) is a single diagnostic category that replaced two separate diagnoses of substance abuse and dependence [
         <a href="#rid4">
          4
         </a>
         ]. The diagnosis of SUD can be specific to a substance, including opioids, stimulants (eg, cocaine), sedative-hypnotic-anxiolytics (eg, benzodiazepines), and alcohol.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Opioid use disorder (OUD)
         </strong>
         – According to the DSM-5, a diagnosis of OUD is ascertained when at least 2 of 11 clinical criteria are met within a 12-month period  (
         <a class="graphic graphic_table graphicRef89993" href="/z/d/graphic/89993.html" rel="external">
          table 1
         </a>
         ). Tolerance and withdrawal are part of the diagnostic criteria for OUD in general, but not applicable to prescribed opioid use that is supervised under a clinician. OUD severity can range from mild to severe, which can help guide treatment planning.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          People with opioid use disorder
         </strong>
         – The term "people with opioid use disorder" models the person-first language that is standard when referring to people living with chronic medical conditions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medications for opioid use disorder (MOUD)
         </strong>
         – The term "medications for opioid use disorder" (MOUD) refers to the three opioid agonist or antagonist medications that are approved by the US Food and Drug Administration to treat OUD:
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         , or
         <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">
          naltrexone
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although the term "medication-assisted treatment" is commonly used to describe SUD treatment programs that offer medications, the authors advise using the term "MOUD" because medications reflect evidence-based treatments, not just as adjunctive to behavioral therapies. MOUD are integral to the long-term treatment for persons with OUD, rather than being an ancillary or short-term treatment.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H413199643">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence
         </strong>
         – In the 2019 National Survey on Drug Use and Health (NSDUH), the prevalence of any substance use disorder (SUD) among the United States population age 12 and older is approximately 7.7 percent, or 19.3 million people [
         <a href="#rid5">
          5
         </a>
         ]. The prevalence of opioid use disorder (OUD) is relatively low in the context of all SUD; in 2019, an estimated 1.6 million people in the United States had OUD. Among people with OUD, approximately 0.5 million have heroin-related OUD, while 1.4 million have opioid analgesic-related OUD. However, the NSDUH is a household survey that may miss people who are incarcerated, not housed, or living in other unstable arrangements. Therefore, some estimates of heroin use are more than five times greater than those reported in the NSDUH [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">
          "Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mortality
         </strong>
         – From 1999 to 2018, the age-adjusted rate of opioid-involved overdose deaths nearly quadrupled in the United States [
         <a href="#rid7">
          7
         </a>
         ]. The biggest driver of overdose deaths has been synthetic opioids (other than
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         ), in particular illicitly manufactured
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         , where the number of attributable overdose deaths swelled from 0.3 to 9.9 per 100,000 standard population from 1999 to 2018. The rate of heroin-related overdose deaths also rose sharply from 1999 to 2017, from 0.7 to 4.9 per 100,000. During this time, overdose deaths involving natural and semi-synthetic opioid analgesics, such as
         <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">
          oxycodone
         </a>
         and
         <a class="drug drug_general" data-topicid="91299" href="/z/d/drug information/91299.html" rel="external">
          hydrocodone
         </a>
         , increased from 1.0 to 4.4 per 100,000. Altogether, opioids accounted for 71 percent of the 70,630 drug overdose deaths in the United States in 2019 [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/99945.html" rel="external">
          "Prevention of lethal opioid overdose in the community", section on 'Prevalence'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Health care utilization
         </strong>
         – Opioid-related emergency department visits, hospital admissions, and related health care costs increased rapidly over the last two decades. In the United States, opioid-related emergency department visits rose by almost 100 percent between 2005 and 2014 [
         <a href="#rid9">
          9
         </a>
         ]. Between 2001 and 2012, heroin overdose-related and prescription opioid-related admissions increased by 1.9- and 2.5-fold respectively; these overdoses accounted for $5.5 billion USD in cumulative hospitalization costs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, skin and soft tissue infections related to intravenous and/or subcutaneous/intramuscular opioid use was associated with a doubling of hospital admissions from four to nine per 100,000 between 1993 and 2010 [
         <a href="#rid10">
          10
         </a>
         ]. Estimated annual hospital admissions for intravenous drug use-associated infective endocarditis increased from 2900 cases in 2013 to more than 20,000 cases in 2017 [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medications for opioid use disorder (MOUD)
         </strong>
         – Mortality among people with OUD is markedly reduced by treatment with MOUD [
         <a href="#rid12">
          12
         </a>
         ], including
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">
          naltrexone
         </a>
         , and
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         . Initiation of methadone or buprenorphine as MOUD after non-fatal opioid overdose is associated with a 38 to 59 percent reduction in opioid-related mortality [
         <a href="#rid13">
          13
         </a>
         ]. In addition, continuing methadone or buprenorphine treatment is associated with a reduction in all-cause mortality compared with discontinuing treatment (25 and 4 fewer deaths per 1000 person-years for methadone and buprenorphine treatment respectively) [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">
          "Opioid use disorder: Pharmacologic management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence-based treatment with MOUD remains underutilized. In 2019, of the 1.6 million people with estimated past-year OUD, only 18 percent reported any receipt of MOUD within the last 12 months [
         <a href="#rid5">
          5
         </a>
         ]. Only 36 percent of specialty substance use treatment facilities in the United States provided any MOUD as of 2016; of these, only 29 percent offered
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         despite its proven efficacy [
         <a href="#rid15">
          15
         </a>
         ]. Conversely,
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         treatment expanded substantially in the primary care setting, with the rate of buprenorphine prescribing increasing from 1.3 to 2.7 people per 100,000 population from 2010 to 2018 [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2209134466">
         <span class="h1">
          PRIMARY CARE MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H1964002340">
         <span class="h2">
          Approach to the patient
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with opioid use disorder (OUD) are a heterogeneous group of people with a wide range of health problems and other care needs. Some patients may be able to maintain stable employment and relationships, while others may have impaired psychosocial functioning with difficulties addressing their chronic health and social issues.
        </p>
        <p>
         Thus, "meeting the patient where they are" is essential to creating an effective provider-patient relationship. Clinicians, as well as office staff, must take a nonjudgmental approach in all interactions with patients who use drugs, and avoidance of
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fnida.nih.gov%2Fnidamed-medical-health-professionals%2Fhealth-professions-education%2Fwords-matter-terms-to-use-avoid-when-talking-about-addiction&amp;token=rBaMQOhEBXNBjJSOI0mIcAmYMmKPzYWx1vDjCBHbqOtq7Bg4DgFjnXEWXF1UL9qAW6hSlqwELV%2BW5lk5S8gSuHCFipMkIribS2c%2F%2FKNibnPLQ8kKtOakQC9BxxTtq%2FxLrwJYpKO23xX9BQMZRkP3zg%3D%3D&amp;TOPIC_ID=126969" target="_blank">
          stigmatizing language
         </a>
         and assumptions about substance use will encourage honest and open communication. Patients may be seeking care for an acute illness or management of chronic medical conditions, but they may not wish to discuss or address their substance use with care providers. Understanding the patients' reasons for accessing care is an essential first step in establishing goals of care.
        </p>
        <p>
         Clinicians should be aware of, assess, and consider certain psychosocial issues that are more commonly seen in patients with OUD, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stigma, which may affect self-disclosure of substance use and motivation for medications for opioid use disorder (MOUD)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Competing priorities that may interfere with engagement in care for chronic health conditions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Trauma, including physical and psychological trauma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Violence, including being a victim of or witness to sexual, interpersonal, family, and community violence
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Housing instability or homelessness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exchange of sex for money or drugs
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Current or prior legal issues, including incarceration
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inadequate psychosocial supports
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H625288972">
         <span class="h2">
          Routine and preventive care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regardless of a patient's substance use, participation in OUD treatment, or openness to engaging in treatment, all patients should receive appropriate management of acute and chronic medical conditions as well as general preventive care, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Follow-up of all chronic health problems.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Guideline-based preventive health screening and administration of recommended vaccinations. (See
         <a class="medical medical_review" href="/z/d/html/97819.html" rel="external">
          "Overview of preventive care in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3884.html" rel="external">
          "Standard immunizations for nonpregnant adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/442.html" rel="external">
          "Immunizations during pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation and provision of contraceptive and reproductive care, if applicable. (See
         <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">
          "Contraception: Counseling and selection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medication reconciliation to identify potential drug-drug interactions that can occur with MOUD, particularly
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         (eg, antiretrovirals, anticonvulsants)  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid17">
          17
         </a>
         ]. Methadone can alter electrical conduction within cardiac tissue leading to QT prolongation and torsades de pointes. The evaluation of patients taking methadone is reviewed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">
          "Opioid use disorder: Pharmacologic management", section on 'Methadone: Opioid agonist'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation of and counseling on medication adherence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Referral and assistance with social needs such as food insecurity and housing instability.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3000448800">
         <span class="h2">
          Specific care concerns for patients with opioid use disorder
         </span>
        </p>
        <p class="headingAnchor" id="H4053940037">
         <span class="h3">
          Assessment of opioid use
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinicians should inquire about and document substance use and treatment history, as well as potential issues related to treatment  (
         <a class="graphic graphic_form graphicRef132149" href="/z/d/graphic/132149.html" rel="external">
          form 1
         </a>
         ). These include (see
         <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">
          "Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7807.html" rel="external">
          "Substance use disorders: Clinical assessment"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Types, amount, frequency, and duration of opioid and other substance use; differentiate between opioids obtained from prescriptions versus other nonmedical sources.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         What was the longest period of abstinence? What contributed to the most recent period of abstinence or use?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When was the last use, and are there any withdrawal symptoms?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Route of use; if injecting, what equipment is the individual using? Are sterile syringes being used, and how are they being obtained?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Overdose history; has the individual experienced slowed breathing or loss of consciousness with substance use? Have they administered or been administered
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         ?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Current and prior treatment history; what MOUD, if any, have been tried previously (
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">
          naltrexone
         </a>
         )? What treatment settings have been tried (eg, residential treatment, intensive outpatient counseling, opioid treatment programs)? Attendance in mutual-help groups (eg, 12-step programs)?
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19050915">
         <span class="h3">
          Risk-factor directed care
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to all routine age-based preventive care recommendations, clinicians should assess the other health care needs of people with OUD based upon possible comorbidities and risk factors, such as co-occurring substance use disorders (SUD), mental health conditions, injection drug use (IDU), sex work, homelessness, and incarceration. Specific health care issues include:
        </p>
        <p class="headingAnchor" id="H1096758077">
         <span class="h4">
          Infectious disease complications
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screening for, offering pre- or postexposure prophylaxis for, and treating human immunodeficiency virus (HIV) infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Screening – Guidelines from the Centers for Disease Control and Prevention recommend at least annual HIV screening for people who inject drugs and for other people with OUD and elevated HIV risk [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">
          "Screening and diagnostic testing for HIV infection", section on 'Whom to test'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Although the incidence of HIV infection among people who inject drugs has dropped from its peak in the 1980s, increasing IDU during the past decade has put many United States counties at high risk for HIV outbreaks [
         <a href="#rid19">
          19
         </a>
         ]. In 2018, IDU accounted for 1 in 15 new HIV infections, with almost 50 percent occurring in individuals ages 13 to 34 years [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prophylaxis – Pre- and postexposure HIV prophylaxis for people who inject drugs is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3768.html" rel="external">
          "Management of nonoccupational exposures to HIV and hepatitis B and C in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113426.html" rel="external">
          "HIV pre-exposure prophylaxis", section on 'Persons who inject drugs'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treatment – Ongoing substance use is not a contraindication to antiretroviral therapy [
         <a href="#rid21">
          21
         </a>
         ]. Despite advances in antiretroviral medications, marginalized groups, including people who inject drugs, have experienced smaller reductions in HIV-related mortality than others [
         <a href="#rid22">
          22
         </a>
         ]. Assuring access to antiretroviral therapy is critical for people with OUD.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In addition to other factors that contribute to antiretroviral therapy choice, simplicity of treatment (eg, single pill regimens), hepatotoxicity, and drug-drug interactions are important considerations for people with OUD. Some first- and second-line regimens contain medications that interact with
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         and potentially
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         through induction of cytochrome P450 (CYP3A4). In particular, some non-nucleoside reverse transcriptase inhibitors (eg,
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         ) can increase methadone metabolism and may require increases in methadone dose to avoid opioid withdrawal symptoms  (
         <a class="graphic graphic_table graphicRef60927" href="/z/d/graphic/60927.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screening and vaccination for hepatitis A and B, and screening for hepatitis C. (See
         <a class="medical medical_review" href="/z/d/html/3680.html" rel="external">
          "Hepatitis B virus: Screening and diagnosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3641.html" rel="external">
          "Hepatitis B virus immunization in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/89950.html" rel="external">
          "Screening and diagnosis of chronic hepatitis C virus infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3900.html" rel="external">
          "Hepatitis A virus infection: Treatment and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Screening – Guidelines from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America recommend that all people who inject drugs be offered annual hepatitis C virus (HCV) testing with HCV antibody (or HCV viral load if the patient has a history of prior infection)  (
         <a class="graphic graphic_algorithm graphicRef127067" href="/z/d/graphic/127067.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Transmission of HCV primarily occurs parenterally, which makes IDU a common risk factor for HCV infection. The incidence of acute HCV infection increased between 2004 and 2017 in the United States due to an increase in IDU [
         <a href="#rid24">
          24,25
         </a>
         ], with IDU accounting for at least 60 percent of acute HCV infections [
         <a href="#rid23">
          23
         </a>
         ]. In one study including three cohorts of people who inject drugs in four United States cities, more than one-third became infected with HCV within five years of IDU initiation [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The equipment used for intranasal insufflation ("snorting") of opioids can also carry and transmit HCV; therefore, people using opioids intranasally should also be offered periodic HCV testing [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treatment – HCV treatment can be offered concomitantly with MOUD. In a clinical trial of 301 people with HCV who were receiving MOUD, 12 weeks of
         <a class="drug drug_general" data-topicid="106574" href="/z/d/drug information/106574.html" rel="external">
          elbasvir-grazoprevir
         </a>
         resulted in cure (sustained virologic response at 12 weeks) in 92 percent of those treated immediately and 90 percent of those receiving delayed treatment [
         <a href="#rid27">
          27
         </a>
         ]. In this clinical trial and another including patients receiving MOUD, substance use during HCV treatment was not associated with worse treatment outcomes [
         <a href="#rid27">
          27,28
         </a>
         ]. Integrating HCV treatment into MOUD treatment programs is feasible and effective [
         <a href="#rid29">
          29,30
         </a>
         ]. Instruments are available to assess psychosocial factors that may affect adherence to HCV medications [
         <a href="#rid31">
          31
         </a>
         ], but HCV treatment should not be withheld based upon substance use alone. (See
         <a class="medical medical_review" href="/z/d/html/15832.html" rel="external">
          "Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Active drug use'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other medical problems related to IDU, such as bacterial infections (endocarditis, osteomyelitis, abscess) and pulmonary complications:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Skin and soft tissue infections, infectious endocarditis, and other systemic infections are common among people who inject drugs [
         <a href="#rid11">
          11,32,33
         </a>
         ]. Abscesses and cellulitis can often be treated in the primary care setting, while more serious infections, such as bacterial endocarditis, osteomyelitis, or necrotizing fasciitis, usually require hospitalization. Pulmonary infections, including pneumonia, may also be associated with illicit or prescribed opioid use [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7660.html" rel="external">
          "Pathogenesis of osteomyelitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7663.html" rel="external">
          "Vertebral osteomyelitis and discitis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/110530.html" rel="external">
          "Acute cellulitis and erysipelas in adults: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4337.html" rel="external">
          "Overview of pulmonary disease in people who inject drugs"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screening for and treatment of latent tuberculosis (see
         <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">
          "Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8017.html" rel="external">
          "Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Some individuals with OUD are at increased risk of latent tuberculosis, particularly those who are experiencing homelessness or are residents or staff of homeless shelters, residents or staff of correctional facilities, or health care workers  (
         <a class="graphic graphic_table graphicRef74584" href="/z/d/graphic/74584.html" rel="external">
          table 4
         </a>
         ). If a decision to treat is made, clinicians should be aware that
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         can interact with the rifamycins (eg,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/491.html" rel="external">
          "Rifamycins (rifampin, rifabutin, rifapentine)", section on 'Drug interactions'
         </a>
         ) and recommend an alternative tuberculosis treatment regimen, adjustment in methadone dose, or change from methadone to
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/8017.html" rel="external">
          "Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection", section on 'Selecting a regimen'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screening for and prevention of sexually transmitted infection, including syphilis, gonorrhea, and chlamydia. (See
         <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">
          "Screening for sexually transmitted infections", section on 'Risk groups'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7595.html" rel="external">
          "Prevention of sexually transmitted infections"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H719093912">
         <span class="h4">
          Coexisting substance use disorders
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screening for alcohol and other substance use, and offering treatment for coexisting SUDs (see
         <a class="medical medical_review" href="/z/d/html/14843.html" rel="external">
          "Screening for unhealthy use of alcohol and other drugs in primary care"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         OUD frequently co-occurs with other SUDs, including alcohol use disorder. Identifying and treating other SUDs are essential components of OUD care; validated instruments such as the Alcohol Use Disorders Identification Test (AUDIT-C) and the Substance Use Brief Screen (SUBS) can be used in the primary care setting as screening tools  (
         <a class="graphic graphic_table graphicRef53246" href="/z/d/graphic/53246.html" rel="external">
          table 5
         </a>
         and
         <a class="graphic graphic_table graphicRef109025" href="/z/d/graphic/109025.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid35">
          35
         </a>
         ]. Decisions to initiate treatment for comorbid SUDs should be patient-centered, and there is little evidence to support delaying treatment of other SUDs to focus on OUD treatment. Addressing co-occurring SUDs concomitantly may improve treatment outcomes for both conditions [
         <a href="#rid36">
          36-38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">
          Naltrexone
         </a>
         is approved by the US Food and Drug Administration for treatment of both alcohol use disorders and OUD and can be used to treat both conditions concomitantly [
         <a href="#rid39">
          39
         </a>
         ]. Because naltrexone is an opioid antagonist, it is contraindicated for patients receiving
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         or
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         treatment. Administering naltrexone to patients taking any opioid agonist medications would lead to opioid withdrawal; initiation of naltrexone for OUD therefore requires an adequate period of abstinence from opioids, which may be challenging for patients. While few studies have directly compared methadone, buprenorphine, and naltrexone for OUD treatment, the strength of evidence supporting methadone and buprenorphine is greater than that supporting naltrexone [
         <a href="#rid13">
          13,40-42
         </a>
         ]. Thus, we consider methadone and buprenorphine as first-line treatment options for patients with OUD, even for those with comorbid alcohol use disorder. However, the long-acting injectable formulation of naltrexone can be a convenient option for some patients with both OUD and alcohol use disorder. (See
         <a class="medical medical_review" href="/z/d/html/108891.html" rel="external">
          "Alcohol use disorder: Treatment overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">
          "Opioid use disorder: Pharmacologic management", section on 'Approach to treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Additionally, benzodiazepine use disorder is common among people with OUD and is strongly associated with opioid overdose mortality due to the potential of prolonged and severe respiratory depression that can occur with coadministration of both agents [
         <a href="#rid43">
          43
         </a>
         ]. Although concurrent benzodiazepine and opioid use increases overdose risk [
         <a href="#rid44">
          44
         </a>
         ],
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         and
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         can be safely administered to patients who take benzodiazepines with careful monitoring [
         <a href="#rid45">
          45
         </a>
         ]. The risks of patient harm from withholding MOUD are greater than the risks of coadministering these medications with benzodiazepines. However, we refer patients with benzodiazepine use disorder to opioid treatment programs that can provide additional monitoring during MOUD. (See
         <a class="medical medical_review" href="/z/d/html/88407.html" rel="external">
          "Benzodiazepine use disorder", section on 'Opioid use disorder'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screening and treatment for tobacco use disorder (see
         <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">
          "Overview of smoking cessation management in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16635.html" rel="external">
          "Pharmacotherapy for smoking cessation in adults"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chronic medical conditions stemming from tobacco use, such as cardiovascular disease, stroke, and cancer, are the leading causes of death among people with OUD [
         <a href="#rid46">
          46
         </a>
         ]. People with OUD infrequently receive evidence-based treatment for tobacco use disorder despite their high burden of tobacco-related illness. Though quit rates are lower among people receiving MOUD than the general population of people who smoke [
         <a href="#rid47">
          47
         </a>
         ], pharmacotherapy, such as
         <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">
          nicotine
         </a>
         replacement therapy (NRT) and
         <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">
          varenicline
         </a>
         have evidence of efficacy when administered with
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         treatment:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In a meta-analysis including nine trials and over 1300 participants, the use of NRT during
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         treatment improved the odds of successful smoking cessation compared with placebo (odds ratio 6.32, 95% CI 1.18-33.75) [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Trials comparing the use of
         <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">
          varenicline
         </a>
         in patients on MOUD have shown inconsistent results. In one trial, varenicline demonstrated greater efficacy than placebo in short-term smoking cessation [
         <a href="#rid49">
          49
         </a>
         ]. Another showed no significant reduction in quit rates with varenicline [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Further, there is no evidence that smoking cessation negatively impacts SUD treatment outcomes [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3146922790">
         <span class="h4">
          Chronic pain
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Comorbid chronic pain (see
         <a class="medical medical_review" href="/z/d/html/2800.html" rel="external">
          "Prevention and management of side effects in patients receiving opioids for chronic pain"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121628.html" rel="external">
          "Management of acute pain in adults with opioid use disorder", section on 'Patients receiving pharmacotherapy for opioid use disorder'
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There is a bidirectional relationship between opioid use and chronic pain. Chronic pain conditions are common among people with OUD, and opioid use may intensify or exacerbate chronic pain. In one study, 37 percent of patients in
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         treatment programs had chronic pain [
         <a href="#rid22">
          22
         </a>
         ]. Patients who initiate prescription opioid analgesics for chronic pain are at risk for developing OUD (see
         <a class="medical medical_review" href="/z/d/html/15236.html" rel="external">
          "Prescription drug misuse: Epidemiology, prevention, identification, and management", section on 'Use disorder'
         </a>
         ). Further, the pharmacologic effects of opioids can contribute to chronic pain through opioid-induced hyperalgesia, in which pain sensitization is enhanced despite opioid therapy [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2800.html" rel="external">
          "Prevention and management of side effects in patients receiving opioids for chronic pain", section on 'Opioid-induced hyperalgesia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Chronic pain treatment for people with OUD should employ comprehensive multimodal approaches, including OUD treatment, nonopioid analgesics, nonpharmacologic treatments such as physical therapy, and other psychosocial treatments directed at pain and comorbid mental health conditions [
         <a href="#rid51">
          51
         </a>
         ]. Patients with OUD and chronic pain are best managed through a multidisciplinary team, and primary care clinicians can coordinate a multidisciplinary approach by referring such patients, particularly those with other psychiatric comorbidities, for management with pain, addiction, and mental health specialists [
         <a href="#rid52">
          52
         </a>
         ]. If a comprehensive multimodal program is unavailable, the inclusion of mental health and pain management specialists in developing a treatment plan may be beneficial.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2635507447">
         <span class="h4">
          Coexisting mental health conditions
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Co-occurring mental health conditions (see
         <a class="medical medical_review" href="/z/d/html/7807.html" rel="external">
          "Substance use disorders: Clinical assessment", section on 'Mental health'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7798.html" rel="external">
          "Co-occurring schizophrenia and substance use disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/99647.html" rel="external">
          "Opioid use disorder: Psychosocial management"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         All people with OUD should receive screening for co-occurring mental health conditions prior to initiating MOUD or during routine primary care.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         OUD is associated with major depressive disorder, anxiety disorders, posttraumatic stress disorder, attention deficit hyperactivity disorder, and personality disorders [
         <a href="#rid53">
          53-56
         </a>
         ]. Data are less consistent regarding the prevalence of bipolar disorder and schizophrenia among people with OUD. In studies that assessed mental health conditions in people seeking
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         treatment and those with prescription OUD, nearly one-half met criteria for at least one co-occurring mental health condition [
         <a href="#rid39">
          39,53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Making a psychiatric diagnosis in people with SUDs requires careful attention to the time course of symptoms and their relation to substance use. Chronic mental health conditions may precede or be caused or exacerbated by substance use. For example, opioids may cause mood symptoms and prolonged exposure can develop into major depressive disorder [
         <a href="#rid57">
          57
         </a>
         ]. Additionally, other substance use, such as cannabis, has been associated with the development of psychosis [
         <a href="#rid58">
          58
         </a>
         ]. There are also likely shared genetic or environmental vulnerabilities that put people at risk for both OUD and chronic mental health conditions [
         <a href="#rid59">
          59
         </a>
         ]. Identifying symptoms that are related to substance use is critical because these symptoms may improve or resolve with the cessation or reduction of substance use.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The mainstay of treatment for co-occurring psychiatric disorders is integrated care with a single clinician or team of clinicians with expertise in both mental health and SUD treatment. The clinician or team should establish a unified patient-centered treatment plan that addresses both mental health and substance use. MOUD remains first-line treatment for patients with OUD and a co-occurring psychiatric diagnosis. Although some evidence supports psychosocial interventions such as group counseling, contingency management, and residential dual diagnosis treatment [
         <a href="#rid60">
          60
         </a>
         ], there is a paucity of high-quality randomized controlled trials to support specific psychosocial interventions for people with severe mental illness and substance misuse [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Most medications used to treat psychiatric conditions can be used safely in patients on MOUD, although prescribers should be aware of the potential for additive sedation and QT prolongation, particularly for patients on
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">
          "Opioid use disorder: Pharmacologic management", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3687685947">
         <span class="h3">
          Harm reduction interventions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Harm reduction refers to interventions aimed at reducing the negative effects related to substance use or other potentially harmful health behaviors [
         <a href="#rid62">
          62
         </a>
         ]. Harm reduction does not condone or condemn substance use; a clinician who practices harm reduction discusses the harms of substance use with the patient and identifies strategies to reduce associated harms. Examples of common harm reduction interventions include designated driver campaigns to reduce morbidity associated with driving while intoxicated and condom use to prevent sexually transmitted infections or pregnancy.
        </p>
        <p>
         We offer harm reduction interventions to all patients with OUD, regardless of their engagement with OUD treatment. For OUD, harm reduction interventions include prescribing of
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         to prevent opioid overdose and referral to syringe service programs to reduce infections associated with unsafe injection. Harm reduction interventions can reduce the morbidity and mortality associated with OUD [
         <a href="#rid63">
          63-70
         </a>
         ] and, in addition, may serve to build provider-patient rapport. Patients with OUD should be encouraged to continue their efforts to limit harmful substance use.
        </p>
        <p>
         The following harm reduction approaches can be employed in the care of patients with OUD:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overdose prevention and
         </strong>
         <strong>
          naloxone
         </strong>
         – We suggest that clinicians provide overdose prevention education and co-prescribe
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         for any patient with OUD, including current and prior history of OUD. In most states in the United States, naloxone can be dispensed at a pharmacy to any individual through a non-patient-specific standing order [
         <a href="#rid71">
          71
         </a>
         ]. Clinicians can also refer patients to local harm reduction service organizations that provide naloxone kits and training. A resource to identify local organizations can be found at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fharmreduction.org%2Fresource-center%2Fharm-reduction-near-you%2F&amp;token=C0sbrWbnpIpeRgxxx3tR4t9NNvhhIFXNqFMDJUTfFNZ3t3r%2BLqBDJBgxkeLP7fQuTZ6iUzBbBQvEiPG5vlzYdK8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=126969" target="_blank">
          National Harm Reduction Coalition
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/99945.html" rel="external">
          "Prevention of lethal opioid overdose in the community"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Overdose prevention education points include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Avoid using opioids alone, particularly intravenous opioids (eg, use with a companion, and take turns)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Do not mix sedating substances (eg, benzodiazepines, alcohol) with opioids
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Go slow (eg, "taste", or sample, a small amount of each new batch of opioids prior to using a larger amount)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Be aware that tolerance may be reduced if not using as much recently as in the past (eg, if just released from the hospital, "detox" facility, or jail) [
         <a href="#rid72">
          72
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Educate close companions regarding the location and use of
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         in case of overdose
        </p>
        <p>
        </p>
        <p>
         The efficacy of overdose prevention including community-based
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         and other opioid antagonists is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/99945.html" rel="external">
          "Prevention of lethal opioid overdose in the community", section on 'Efficacy'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Safer injection
         </strong>
         – We suggest that
         <strong>
         </strong>
         clinicians provide education to patients with OUD on safer injection practices, including advice to rotate injection sites, clean the skin prior to injecting, and not to reuse syringes and needles, and referral to a syringe service program. Safer injection practices may reduce the morbidity and mortality associated with IDU and are not associated with increased drug use [
         <a href="#rid73">
          73-75
         </a>
         ]. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a meta-analysis including six observational studies, use of a syringe service program was associated with a decreased risk of acquiring HIV infection (risk ratio [RR] 0.42, 95% CI 0.22-0.81) [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a 2017 systematic review including five observational studies from North America and Europe, although the availability of syringe service programs was not associated with a reduction in HCV acquisition, in certain European regions, the presence of high-coverage syringe service programs was associated with a 76 percent reduction in HCV (RR 0.24, 95% CI 0.09-0.62) [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a retrospective study evaluating the prevalence of maternal HCV seropositivity in an Ohio county, introduction of a local syringe service program was associated with a reduction in the rate of increase in maternal HCV infections. From 2006 to 2011, the rate increased 137 percent; after the introduction of the syringe program in 2011, the rate of maternal HCV only increased 12 percent in the county over the next four years. Contiguous counties also experienced similar improvements in maternal HCV rates, while regional, noncontiguous counties continued to have elevated rates of infection [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a randomized controlled trial including 600 people who inject drugs, use of a syringe service program was not associated with increased drug use compared with those receiving usual care [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In some jurisdictions, clinicians may be able to prescribe sterile syringes, needles, and sharps containers to people who inject drugs [
         <a href="#rid77">
          77
         </a>
         ]. However, in most US states, sterile syringes and injection equipment are considered illegal drug paraphernalia, even when prescribed by clinicians or accessed from pharmacies. As such, authorized syringe service programs play an important role in many communities. Syringe service programs provide sterile needles, syringes, injection supplies, and often other health-promoting services (eg, HIV testing) to registered participants. Clinicians can refer to organizations such as
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fharmreduction.org%2Fresource-center%2Fharm-reduction-near-you%2F&amp;token=C0sbrWbnpIpeRgxxx3tR4t9NNvhhIFXNqFMDJUTfFNZ3t3r%2BLqBDJBgxkeLP7fQuTZ6iUzBbBQvEiPG5vlzYdK8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=126969" target="_blank">
          National Harm Reduction Coalition
         </a>
         or their local health departments for more information about syringe services programs in their area.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Overdose prevention centers, also known as supervised injection sites, are sanctioned facilities that allow people to consume preobtained drugs under the supervision of trained staff. They are intended to reduce harms associated with drug consumption, and they have been associated with positive outcomes in countries around the world [
         <a href="#rid78">
          78
         </a>
         ]. The first sanctioned overdose prevention center in the United States opened in New York City in 2021 [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1707441797">
         <span class="h1">
          MANAGING MEDICATIONS FOR OPIOID USE DISORDER IN PRIMARY CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Care for people with opioid use disorder (OUD) can be optimized by integrating medications for opioid use disorder (MOUD) into the primary care setting.
        </p>
        <p>
         For many people with OUD, this is preferred, likely because of familiarity, accessibility, and lower stigma associated with integrated primary care addiction treatment [
         <a href="#rid80">
          80
         </a>
         ]. Receipt of MOUD in primary care is associated with high patient satisfaction [
         <a href="#rid81">
          81
         </a>
         ], particularly in the context of strong patient-provider relationships and a supportive patient-centered care environment. Referral to specialty substance use treatment programs, however, may be appropriate for people with more intensive mental health or psychosocial needs, as additional supports and services may be available through these programs (see
         <a class="medical medical_review" href="/z/d/html/7799.html" rel="external">
          "Substance use disorders: Determining appropriate level of care for treatment"
         </a>
         ). However, for some individuals, referral to an outside program may be unsuccessful due to lack of access or challenges with patient engagement, and as a result leave some without OUD treatment.
        </p>
        <p>
         Primary care clinicians should inquire if patients are receiving MOUD outside of the primary care setting. In addition, clinicians should review state prescription drug monitoring programs (PDMPs) for
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         prescriptions as well as other opioids and non-opioid controlled substances dispensed through community pharmacies. Of note,
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         and buprenorphine dispensed through opioid treatment programs are not routinely listed on PDMPs; federal amendments permitting PDMP reporting by opioid treatment programs were enacted in 2020, although reporting of these medications is not mandatory.
        </p>
        <p>
         For patients receiving MOUD from another provider, collaboration between providers is ideal. Clinicians may need to review records of prior substance use treatment to help inform current treatment planning. Clinicians should be aware that federal law (42-CFR-Part 2) protects the confidentiality of substance use treatment records at specialty treatment programs, and written consent from a patient must be obtained to access, review, and discuss details specific to substance use treatment outside of primary care settings.
        </p>
        <p class="headingAnchor" id="H3647067776">
         <span class="h2">
          Initiating MOUD
         </span>
         <span class="headingEndMark">
          —
         </span>
         When offering to initiate MOUD, the primary care clinician may best frame concerns about the individual's substance use in terms of specific health risks. Many people who use drugs are ambivalent about their use. Even if treatment is initially declined, the clinician should continue to highlight the availability of MOUD at future appointments because the patient may accept treatment at some point. (See
         <a class="medical medical_review" href="/z/d/html/16752.html" rel="external">
          "Substance use disorders: Motivational interviewing"
         </a>
         .)
        </p>
        <p>
         Primary care clinicians should consult and be familiar with national guidelines and implementation guides for the delivery of MOUD in office-based settings, including primary care. Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fciswh.org%2Fwp-content%2Fuploads%2F2017%2F06%2FBuprenorphine-Implementation-Manual-for-Primary-Care-Settings-.pdf&amp;token=YzCPDVB%2FY7EQA7PU%2BGqjaeLs%2Fc5f5thgywoLwD5DQvDJdjLfzEAnzhTDNy650f8rdhXaa9jZOZPwxg89%2FuDJZ5N%2B3StRJJoosjnpV2yjYNDmL34sz%2FFg5CM6xNTW%2BmTq1%2BNROQMuldP%2BLD8tzhNuFw%3D%3D&amp;TOPIC_ID=126969" target="_blank">
          Integrating Buprenorphine Treatment for Opioid Use Disorder in Primary Care
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fpcssnow.org%2Fclinical-tools%2F&amp;token=fCrgfzN7pYf%2FbgtkU9ShI2L5WevFbBUw5L3hldHzjAbHBXeYDrU7ZEA0tfJlwhFq&amp;TOPIC_ID=126969" target="_blank">
          Provider Clinical Support System: Clinical Tools
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.addictiontraining.org%2Fresources%2F&amp;token=SViNM5hSChi%2FYi%2B1yOUivZRaQjFBBzXbt0oMTpeYM2Xi%2BNZydetO%2FkZUOW4B1X6V%2BxqW5GTOa2GjGFv4HP6PMw%3D%3D&amp;TOPIC_ID=126969" target="_blank">
          Boston Medical Center Office Based Addiction Treatment Training and Technical Assistance
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.asam.org%2Fquality-care%2Fclinical-guidelines%2Fnational-practice-guideline&amp;token=OJSLrEgQBEKraqfuEEEqp4q7P0Sa3odV%2BBzkUENpcgeZTEyZE7Ve4wgD2xKZNg6M7U1Uz5G1YnWCIiWvIKeR2sQqOQ5zY%2FcLVsGwUl%2BVKgE%3D&amp;TOPIC_ID=126969" target="_blank">
          The American Society of Addiction Medicine National Practice Guideline For the Treatment of Opioid Use Disorder
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.samhsa.gov%2Fmedications-substance-use-disorders%2Fmedications-counseling-related-conditions&amp;token=21TkZapWWq6T%2BeLGtU29JPfbzodRhFaLMxfraxcouiR0Xhe1bVkecnWTsVeFFTtQXnny10bm9lQbRmCSpfeYmicSITpdgmtRA1XkIVnX4TgzSyYfig9qxgpeFr85vU7C&amp;TOPIC_ID=126969" target="_blank">
          SAMHSA Medications for Opioid Use Disorder
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.samhsa.gov%2Fsites%2Fdefault%2Ffiles%2Fquick-start-guide.pdf&amp;token=HZAQww4cYtcUzeae1JjrWNmUXL964%2FHNyeg1N0uaPa2yazan7zhmWDbx%2BAsTbpXQvmPaoqa2T7o7nRs%2FrTC6Til2lBbQ22e1yO7mzxAAAHY%3D&amp;TOPIC_ID=126969" target="_blank">
          SAMHSA Buprenorphine Quick Start Guide
         </a>
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          Buprenorphine
         </a>
         and
         <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">
          naltrexone
         </a>
         are the primary MOUD modalities that can be prescribed in the primary care setting since
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         treatment for OUD must be delivered through federally regulated opioid treatment programs. Patients with OUD who need more intensive services than can be provided through primary care settings can be referred to a local opioid treatment program or other specialty substance use treatment programs. In the United States, opioid treatment programs are the only settings through which patients with OUD can access methadone treatment; they also provide individual and/or group counseling. Common reasons why patients may benefit from referral outside of primary care include preference for or prior success with methadone treatment; unstable, co-occurring severe mental illness; or severe alcohol or benzodiazepines use disorder that can benefit from closer monitoring and intensive services. (See
         <a class="medical medical_review" href="/z/d/html/7799.html" rel="external">
          "Substance use disorders: Determining appropriate level of care for treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/108803.html" rel="external">
          "Opioid use disorder: Treatment overview"
         </a>
         .)
        </p>
        <p>
         Telemedicine visits can also be employed to deliver care for people with MOUD, although this has generally been limited to rural health settings where travel distances between the patient and provider may be prohibitive [
         <a href="#rid82">
          82
         </a>
         ]. Federal regulations limiting telemedicine for
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         treatment initiation were waived under the declaration of public health emergency for coronavirus disease 2019 (COVID-19). Subsequently, the use of telemedicine for MOUD delivery was expanded into nonrural health settings [
         <a href="#rid83">
          83,84
         </a>
         ], although outcomes have not been rigorously evaluated [
         <a href="#rid85">
          85,86
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3049701900">
         <span class="h2">
          Maintaining MOUD
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients receiving MOUD, primary care clinicians should acknowledge OUD as a chronic medical condition at all visits. As with any chronic medical problem, the clinician should inquire about recent control or problems with opioid use, including cravings and relapse. Additionally, the clinician should ask about any changes in MOUD therapy and side effects; the
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         dose can be titrated according to the patient's symptoms (see
         <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">
          "Opioid use disorder: Pharmacologic management", section on 'Buprenorphine: Opioid agonist'
         </a>
         ). Patients who are undergoing buprenorphine titration or are experiencing side effects should have close follow-up (eg, within two to four weeks). Otherwise, for patients doing well on a stable dose, without significant cravings or relapse, the clinician may space out follow-up visits and provide interim refills.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicology testing
         </strong>
         – When treating OUD, toxicology tests (saliva or urine) may provide important clinical information to complement patients' self-report and provider assessment. Clinical guidelines recommend the use of toxicology tests in addiction treatment; however, evidence that support the use of toxicology testing in improving patient outcomes is limited [
         <a href="#rid87">
          87
         </a>
         ]. Clinicians should be thoughtful in the use of these tests to maintain a patient-centered rather than a punitive treatment approach. Many providers have limited knowledge on the interpretation of toxicology results [
         <a href="#rid88">
          88
         </a>
         ], and the use of toxicology may introduce disparities in care, as racial biases are evident in the ordering of these tests [
         <a href="#rid89">
          89
         </a>
         ]. When considering toxicology tests, clinicians should:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Understand the test characteristics, costs, and indications for toxicology tests. As examples, synthetic opioids require tests that are specific to the opioid (eg,
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">
          oxycodone
         </a>
         , and
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         are not detected with screening tests for "opiates" but require specific screening and/or confirmatory tests for each of them)  (
         <a class="graphic graphic_table graphicRef95110" href="/z/d/graphic/95110.html" rel="external">
          table 7
         </a>
         ). Guidance on toxicology interpretation is available and should be part of the clinical toolkit for OUD treatment in primary care [
         <a href="#rid90">
          90-93
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13846.html" rel="external">
          "Testing for drugs of abuse (DOAs)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Set clear expectations with patients about how toxicology tests fit in as a component of their treatment plan. Having transparent discussions about how to navigate unexpected (ie, positive) toxicology results is essential as a part of ongoing treatment. Continued use of illicit opioids may occur even after initiating MOUD. While some patients may benefit from referral to a more intensive treatment setting, maintenance of MOUD should not be solely dependent on negative toxicology testing. (See
         <a class="medical medical_review" href="/z/d/html/108803.html" rel="external">
          "Opioid use disorder: Treatment overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Concerns over medication diversion
         </strong>
         – Clinicians may have concerns over medication diversion, which is selling or sharing prescribed medication with someone other than the individual for whom it was intended.
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          Buprenorphine
         </a>
         diversion does occur; however, diversion of buprenorphine occurs at similar rates as other commonly prescribed medications. In the general population, commonly diverted medications include allergy medications, antibiotics, and opioid analgesics [
         <a href="#rid94">
          94
         </a>
         ]. Relative to the diversion of full opioid agonists, however, diversion of buprenorphine, a partial agonist, is less common [
         <a href="#rid95">
          95,96
         </a>
         ]. More importantly, buprenorphine diversion may occur because of the lack of access to buprenorphine treatment. For example, many individuals with OUD who are not enrolled in a formal treatment program have difficulty affording or locating available providers [
         <a href="#rid97">
          97-99
         </a>
         ]; they report taking diverted buprenorphine to manage opioid withdrawal or in other ways consistent with therapeutic use [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While there are no evidence-based ways to prevent diversion, primary care clinicians can implement the following practical strategies to mitigate diversion:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treatment agreements that explicitly discuss expectations of
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         treatment, as well as consequences for diversion activity
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Close follow-up for patients who are new or unstable in treatment (ie, short duration between scheduled visits)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Limit the amount of medication per prescription for patients who are new or unstable in treatment
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Offer long-acting formulations such as injectable
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Have transparent discussions with patients that prioritize harm reduction as well as medication refills and safe storage
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2182241231">
         <span class="h3">
          Managing medication side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Constipation is a common side effect of opioid agonist medications and may affect quality of life. In clinical practice, most constipation from
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         or
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         treatment can be managed with fiber supplementation or prokinetic or osmotic laxatives (eg,
         <a class="drug drug_general" data-topicid="8815" href="/z/d/drug information/8815.html" rel="external">
          bisacodyl
         </a>
         ,
         <a class="drug drug_general" data-topicid="10260" href="/z/d/drug information/10260.html" rel="external">
          senna
         </a>
         , or polyethylene glycol); peripherally acting mu-opioid receptor antagonists are usually not necessary [
         <a href="#rid101">
          101
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2636.html" rel="external">
          "Management of chronic constipation in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H726113681">
         <span class="h2">
          Optimizing psychosocial support for MOUD
         </span>
         <span class="headingEndMark">
          —
         </span>
         The delivery of MOUD can be enhanced through engagement of a multidisciplinary team that includes prescribing clinicians and clinical coordinators; these coordinators are key to supporting patients and can facilitate medical and behavioral health needs. Additional team members may include nurses, pharmacists, or social workers who are integrated in the primary care setting.
        </p>
        <p>
         Participation in counseling and other psychosocial treatment modalities should also be explored with the patient. Clinical trials that established
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         efficacy delivered in the primary care setting have used a standardized but focused approach to psychosocial counseling [
         <a href="#rid102">
          102,103
         </a>
         ]. A typical approach will include 15 minutes of counseling delivered by a primary care clinician or a care coordinator addressing current substance use, OUD symptoms, and relapse prevention [
         <a href="#rid104">
          104
         </a>
         ]. In randomized controlled trials, more intensive psychosocial counseling has not been shown to improve buprenorphine treatment outcomes in comparison with medication management alone [
         <a href="#rid105">
          105-107
         </a>
         ]. However, many people initiating buprenorphine treatment request and may benefit from additional psychosocial counseling [
         <a href="#rid108">
          108
         </a>
         ]. In combination with MOUD, participation in psychosocial treatment can be important for people with co-occurring mental health conditions. Further, the primary care clinician can enhance patient rapport by addressing the patient's experience with psychosocial treatment in addition to managing MOUD.
        </p>
        <p>
         Other patients may choose participation in mutual-help groups such as 12-step programs which provide peer-based psychosocial support. As with other psychosocial treatments, asking questions about the patient's experience in the program (eg, group attendance, presence of a sponsor, commitment to a home group) will emphasize the clinician's interest in the patient's use of peer support systems. Clinicians should be aware that
         <em>
         </em>
         some mutual self-help groups may perpetuate stigmatizing attitudes toward MOUD [
         <a href="#rid109">
          109
         </a>
         ], and asking patients about this can be helpful. All patients should be encouraged to continue MOUD because premature cessation of MOUD can increase overdose risk [
         <a href="#rid110">
          110,111
         </a>
         ].
        </p>
        <p>
         Psychosocial treatments for OUD are reviewed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/99647.html" rel="external">
          "Opioid use disorder: Psychosocial management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3535603405">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113643.html" rel="external">
          "Society guideline links: Opioid use disorder and withdrawal"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1589035705">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/16997.html" rel="external">
          "Patient education: Prescription drug misuse (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/95131.html" rel="external">
          "Patient education: Opioid use disorder (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1430388682">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Engage patients in opioid use disorder (OUD) treatment
         </strong>
         – OUD affects people who use prescription opioids, as well as those who use heroin or other illicit opioids, especially illicitly manufactured
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         . Each point of clinical care can represent an important opportunity to make an OUD diagnosis, offer evidence-based treatment, and connect an individual with ongoing care. Person-centered terminology should be used when caring for people with OUD; stigmatizing language (eg, "substance abuser," "addict") perpetuates negative perceptions and attitudes and is a commonly cited barrier to why people with OUD are not engaged in treatment. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Definitions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Routine health care and specific care issues for adults with opioid use disorder
         </strong>
         – Regardless of a patient's substance use, participation in OUD treatment, or openness to engaging in treatment, all patients should receive appropriate management of acute and chronic medical conditions as well as general preventive care. Clinicians should inquire about and document substance use and treatment history, as well as potential issues related to treatment  (
         <a class="graphic graphic_form graphicRef132149" href="/z/d/graphic/132149.html" rel="external">
          form 1
         </a>
         ). Clinicians should also assess other health care needs based upon possible comorbidities and risk factors, such as co-occurring substance use disorders (SUD) and mental health conditions, injection drug use (IDU), sex work, homelessness, and incarceration. (See
         <a class="local">
          'Routine and preventive care'
         </a>
         above and
         <a class="local">
          'Specific care concerns for patients with opioid use disorder'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Harm reduction interventions for all patients
         </strong>
         – We offer harm reduction interventions to all patients with OUD, regardless of their engagement with OUD treatment. We suggest overdose prevention interventions (including education and
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         prescriptions) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ), as well as safer-injection interventions (including patient education and referral to a syringe service program) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Harm reduction interventions reduce the morbidity and mortality associated with OUD and are not associated with increased drug use. (See
         <a class="local">
          'Harm reduction interventions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medications for opioid use disorder (MOUD) in the primary care setting
         </strong>
         – Care for people with OUD can be optimized by integrating MOUD into the primary care setting. Primary care clinicians should consult and be familiar with national guidelines and implementation guides for the delivery of MOUD in office-based settings. Certain patients may benefit from referral outside of primary care, such as those with a preference for or prior success with
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         treatment; and those with unstable, co-occurring severe mental illness or severe alcohol or benzodiazepines use disorder that can benefit from closer monitoring and intensive services. (See
         <a class="local">
          'Managing medications for opioid use disorder in primary care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Optimize psychosocial support
         </strong>
         – The delivery of MOUD can be enhanced through engagement of a multidisciplinary team that includes prescribing clinicians and clinical coordinators; these coordinators are key to supporting patients and can facilitate medical and behavioral health needs. Participation in counseling and other psychosocial treatment modalities should also be explored with the patient. (See
         <a class="local">
          'Optimizing psychosocial support for MOUD'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kelly JF, Westerhoff CM. Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. Int J Drug Policy 2010; 21:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsai AC, Kiang MV, Barnett ML, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med 2019; 16:e1002969.
          </a>
         </li>
         <li class="breakAll">
          American Society of Addiction Medicine. Definition of addiction. Available at: https://www.asam.org/Quality-Science/definition-of-addiction (Accessed on January 19, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasin DS, O'Brien CP, Auriacombe M, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry 2013; 170:834.
          </a>
         </li>
         <li class="breakAll">
          Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health. US Department of Health and Human Services 2020. Available at: https://store.samhsa.gov/product/key-substance-use-and-mental-health-indicators-in-the-united-states-results-from-the-2019-national-survey-on-Drug-Use-and-Health/PEP20-07-01-001 (Accessed on January 19, 2021).
         </li>
         <li class="breakAll">
          Midgette G, Davenpotr S, Caulkins JP, Kilmer B. What America's users spend on illegal drugs, 2006-2016. RAND Corporation 2019. Available at: https://www.rand.org/pubs/research_reports/RR3140.html (Accessed on January 19, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hedegaard H, Miniño AM, Warner M. Drug Overdose Deaths in the United States, 1999-2018. NCHS Data Brief 2020; :1.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Drug overdose deaths. Available at: https://www.cdc.gov/drugoverdose/data/statedeaths.html (Accessed on June 18, 2021).
         </li>
         <li class="breakAll">
          Weiss AJ, Elixhauser A, Barrett ML, et al. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs, Agency for Healthcare Research and Quality (US), 2006.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciccarone D, Unick GJ, Cohen JK, et al. Nationwide increase in hospitalizations for heroin-related soft tissue infections: Associations with structural market conditions. Drug Alcohol Depend 2016; 163:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           See I, Gokhale RH, Geller A, et al. National Public Health Burden Estimates of Endocarditis and Skin and Soft-Tissue Infections Related to Injection Drug Use: A Review. J Infect Dis 2020; 222:S429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santo T Jr, Clark B, Hickman M, et al. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. JAMA Psychiatry 2021; 78:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larochelle MR, Bernson D, Land T, et al. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. Ann Intern Med 2018; 169:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017; 357:j1550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mojtabai R, Mauro C, Wall MM, et al. Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities. Health Aff (Millwood) 2019; 38:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olfson M, Zhang V, Schoenbaum M, King M. Buprenorphine Treatment By Primary Care Providers, Psychiatrists, Addiction Specialists, And Others. Health Aff (Millwood) 2020; 39:984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 2010; 19:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiese AD, Griffin MR, Schaffner W, et al. Opioid Analgesic Use and Risk for Invasive Pneumococcal Diseases: A Nested Case-Control Study. Ann Intern Med 2018; 168:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV 2017; 4:e349.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. HIV among people who inject drugs. Available at: https://www.cdc.gov/hiv/group/hiv-idu.html (Accessed on July 14, 2021).
         </li>
         <li class="breakAll">
          HIV.gov. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Available at: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/22/substance-use-disorders-and-hiv (Accessed on January 19, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenblum A, Joseph H, Fong C, et al. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA 2003; 289:2370.
          </a>
         </li>
         <li class="breakAll">
          American Association for the Study of Liver Diseases, Infectious Diseases Society of America. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. Available at: https://www.hcvguidelines.org (Accessed on January 19, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amon JJ, Garfein RS, Ahdieh-Grant L, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis 2008; 46:1852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dore GJ, Altice F, Litwin AH, et al. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Ann Intern Med 2016; 165:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akiyama MJ, Norton BL, Arnsten JH, et al. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial. Ann Intern Med 2019; 170:594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norton BL, Beitin A, Glenn M, et al. Retention in buprenorphine treatment is associated with improved HCV care outcomes. J Subst Abuse Treat 2017; 75:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norton BL, Akiyama MJ, Zamor PJ, Litwin AH. Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice. Infect Dis Clin North Am 2018; 32:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Handel MM, Rose CE, Hallisey EJ, et al. County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States. J Acquir Immune Defic Syndr 2016; 73:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55:1.
          </a>
         </li>
         <li class="breakAll">
          Weiss JJ. PREP-C: Psychosocial Readiness Evaluation and Preparation for hepatits C Treatment. Mount Sinai School of Medicine. Available at: https://prepc.org/model (Accessed on January 19, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson KA, Bohm MK, Brooks JT, et al. Invasive Methicillin-Resistant Staphylococcus aureus Infections Among Persons Who Inject Drugs - Six Sites, 2005-2016. MMWR Morb Mortal Wkly Rep 2018; 67:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marks LR, Nolan NS, Liang SY, et al. Infectious Complications of Injection Drug Use. Med Clin North Am 2022; 106:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edlund MJ, Martin BC, Russo JE, et al. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain 2014; 30:557.
          </a>
         </li>
         <li class="breakAll">
          New York State Department of Health AIDS Institute. Clinical guidelines program: Substance use screening and risk assessment in adults. Available at: https://www.hivguidelines.org/substance-use/su-screening/#tab_4 (Accessed on January 19, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soyka M. Alcohol use disorders in opioid maintenance therapy: prevalence, clinical correlates and treatment. Eur Addict Res 2015; 21:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan MA, Covey LS. Current perspectives on smoking cessation among substance abusers. Curr Psychiatry Rep 2002; 4:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKelvey K, Thrul J, Ramo D. Impact of quitting smoking and smoking cessation treatment on substance use outcomes: An updated and narrative review. Addict Behav 2017; 65:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gros DF, Milanak ME, Brady KT, Back SE. Frequency and severity of comorbid mood and anxiety disorders in prescription opioid dependence. Am J Addict 2013; 22:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakeman SE, Larochelle MR, Ameli O, et al. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open 2020; 3:e1920622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; :CD002207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarvis BP, Holtyn AF, Subramaniam S, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction 2018; 113:1188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction 2016; 111:1160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tori ME, Larochelle MR, Naimi TS. Alcohol or Benzodiazepine Co-involvement With Opioid Overdose Deaths in the United States, 1999-2017. JAMA Netw Open 2020; 3:e202361.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: Careful medication management can reduce risks. Available at: https://www.fda.gov/media/107888/download (Accessed on May 24, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein MD, Caviness CM, Kurth ME, et al. Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. Drug Alcohol Depend 2013; 133:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shoptaw S, Rotheram-Fuller E, Yang X, et al. Smoking cessation in methadone maintenance. Addiction 2002; 97:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yee A, Hoong MC, Joyce YC, Loh HS. Smoking Cessation Among Methadone-Maintained Patients: A Meta-Analysis. Subst Use Misuse 2018; 53:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nahvi S, Ning Y, Segal KS, et al. Varenicline efficacy and safety among methadone maintained smokers: a randomized placebo-controlled trial. Addiction 2014; 109:1554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hser YI, Mooney LJ, Saxon AJ, et al. High Mortality Among Patients With Opioid Use Disorder in a Large Healthcare System. J Addict Med 2017; 11:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend 2012; 125:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liebschutz J, Beers D, Lange A. Managing Chronic Pain in Patients with Opioid Dependence. Curr Treat Options Psychiatry 2014; 1:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brooner RK, King VL, Kidorf M, et al. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 1997; 54:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen D, Smith ML, Reynolds CF 3rd. The prevalence of mental and physical health disorders among older methadone patients. Am J Geriatr Psychiatry 2008; 16:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roncero C, Barral C, Rodríguez-Cintas L, et al. Psychiatric comorbidities in opioid-dependent patients undergoing a replacement therapy programme in Spain: The PROTEUS study. Psychiatry Res 2016; 243:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carpentier PJ, Krabbe PF, van Gogh MT, et al. Psychiatric comorbidity reduces quality of life in chronic methadone maintained patients. Am J Addict 2009; 18:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer B, Murphy Y, Kurdyak P, Goldner EM. Depression - A major but neglected consequence contributing to the health toll from prescription opioids? Psychiatry Res 2016; 243:331.
          </a>
         </li>
         <li class="breakAll">
          The National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. 2017. Available at: https://www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state (Accessed on November 29, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kendler KS, Prescott CA, Myers J, Neale MC. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Arch Gen Psychiatry 2003; 60:929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drake RE, O'Neal EL, Wallach MA. A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. J Subst Abuse Treat 2008; 34:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunt GE, Siegfried N, Morley K, et al. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev 2019; 12:CD001088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawk M, Coulter RWS, Egan JE, et al. Harm reduction principles for healthcare settings. Harm Reduct J 2017; 14:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction 2016; 111:1177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abouk R, Pacula RL, Powell D. Association Between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose. JAMA Intern Med 2019; 179:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013; 346:f174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Platt L, Minozzi S, Reed J, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev 2017; 9:CD012021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Den Berg C, Smit C, Van Brussel G, et al. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102:1454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossi RM, Brady MJ, Hall ES, Warshak CR. Effect of Needle Exchange Program on Maternal Hepatitis C Virus Prevalence. Am J Perinatol 2020; 37:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wodak A, Maher L. The effectiveness of harm reduction in preventing HIV among injecting drug users. N S W Public Health Bull 2010; 21:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strathdee SA, Ricketts EP, Huettner S, et al. Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: Results from a community-based behavioral intervention trial. Drug Alcohol Depend 2006; 83:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis C, Carr D. State legal innovations to encourage naloxone dispensing. J Am Pharm Assoc (2003) 2017; 57:S180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Binswanger IA, Stern MF, Deyo RA, et al. Release from prison--a high risk of death for former inmates. N Engl J Med 2007; 356:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse 2006; 41:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandes RM, Cary M, Duarte G, et al. Effectiveness of needle and syringe Programmes in people who inject drugs - An overview of systematic reviews. BMC Public Health 2017; 17:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher DG, Fenaughty AM, Cagle HH, Wells RS. Needle exchange and injection drug use frequency: a randomized clinical trial. J Acquir Immune Defic Syndr 2003; 33:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aspinall EJ, Nambiar D, Goldberg DJ, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol 2014; 43:235.
          </a>
         </li>
         <li class="breakAll">
          The Policy Surveillance Program. Syringe service program laws. Available at: http://lawatlas.org/datasets/syringe-services-programs-laws (Accessed on June 25, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Potier C, Laprévote V, Dubois-Arber F, et al. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend 2014; 145:48.
          </a>
         </li>
         <li class="breakAll">
          The Official City Website of New York. Mayor de Blasio announces nation's first overdose prevention center services to open in New York City. November 2021. Available at: https://www1.nyc.gov/office-of-the-mayor/news/793-21/mayor-de-blasio-nation-s-first-overdose-prevention-center-services-open-new-york (Accessed on November 30, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barry CL, Epstein AJ, Fiellin DA, et al. Estimating demand for primary care-based treatment for substance and alcohol use disorders. Addiction 2016; 111:1376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korthuis PT, Gregg J, Rogers WE, et al. Patients' Reasons for Choosing Office-based Buprenorphine: Preference for Patient-Centered Care. J Addict Med 2010; 4:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunet N, Moore DT, Lendvai Wischik D, et al. Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine. Subst Abus 2022; 43:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris M, Johnson S, Mackin S, et al. Low Barrier Tele-Buprenorphine in the Time of COVID-19: A Case Report. J Addict Med 2020; 14:e136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uscher-Pines L, Sousa J, Raja P, et al. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine. J Subst Abuse Treat 2020; 118:108124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tofighi B, McNeely J, Walzer D, et al. A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System's Initiative to Expand Treatment Access During the COVID-19 Pandemic. J Addict Med 2022; 16:e40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchheit BM, Wheelock H, Lee A, et al. Low-barrier buprenorphine during the COVID-19 pandemic: A rapid transition to on-demand telemedicine with wide-ranging effects. J Subst Abuse Treat 2021; 131:108444.
          </a>
         </li>
         <li class="breakAll">
          American Society of Addiction Medicine. Consensus statement: Appropriate use of drug testing in clinical addiction medicine. Available at: https://www.asam.org/docs/default-source/quality-science/the-asam-appropriate-use-of-drug-testing-in-clinical-addiction-medicine-full-document.pdf (Accessed on June 18, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Starrels JL, Fox AD, Kunins HV, Cunningham CO. They don't know what they don't know: internal medicine residents' knowledge and confidence in urine drug test interpretation for patients with chronic pain. J Gen Intern Med 2012; 27:1521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaither JR, Gordon K, Crystal S, et al. Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients. Drug Alcohol Depend 2018; 192:371.
          </a>
         </li>
         <li class="breakAll">
          Boston Medical Center. Performing urine drug tests. Available at: http://mytopcare.org/prescribers/about-urine-drug-tests/ (Accessed on January 19, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Standridge JB, Adams SM, Zotos AP. Urine drug screening: a valuable office procedure. Am Fam Physician 2010; 81:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenore PL. Advanced urine toxicology testing. J Addict Dis 2010; 29:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donroe JH, Holt SR, O'Connor PG, et al. Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice. Drug Alcohol Depend 2017; 180:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldsworthy RC, Schwartz NC, Mayhorn CB. Beyond abuse and exposure: framing the impact of prescription-medication sharing. Am J Public Health 2008; 98:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cicero TJ, Surratt HL, Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J Opioid Manag 2007; 3:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paone D, Tuazon E, Stajic M, et al. Buprenorphine infrequently found in fatal overdose in New York City. Drug Alcohol Depend 2015; 155:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bazazi AR, Yokell M, Fu JJ, et al. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J Addict Med 2011; 5:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox AD, Chamberlain A, Sohler NL, et al. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. J Subst Abuse Treat 2015; 48:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lofwall MR, Havens JR. Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine. Drug Alcohol Depend 2012; 126:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cicero TJ, Ellis MS, Chilcoat HD. Understanding the use of diverted buprenorphine. Drug Alcohol Depend 2018; 193:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain 2014; 15:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006; 355:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiellin DA, Pantalon MV, Pakes JP, et al. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 2002; 28:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med 2011; 171:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 2011; 68:1238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiellin DA, Barry DT, Sullivan LE, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med 2013; 126:74.e11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ling W, Hillhouse M, Ang A, et al. Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction 2013; 108:1788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carroll KM, Weiss RD. The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review. Am J Psychiatry 2017; 174:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monico LB, Gryczynski J, Mitchell SG, et al. Buprenorphine Treatment and 12-step Meeting Attendance: Conflicts, Compatibilities, and Patient Outcomes. J Subst Abuse Treat 2015; 57:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo-Ciganic WH, Gellad WF, Gordon AJ, et al. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction 2016; 111:892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang HY, Krawczyk N, Schneider KE, et al. A predictive risk model for nonfatal opioid overdose in a statewide population of buprenorphine patients. Drug Alcohol Depend 2019; 201:127.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 126969 Version 19.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20005692" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31770387" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Stigma as a fundamental hindrance to the United States opioid overdose crisis response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31770387" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Stigma as a fundamental hindrance to the United States opioid overdose crisis response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23903334" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : DSM-5 criteria for substance use disorders: recommendations and rationale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23903334" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : DSM-5 criteria for substance use disorders: recommendations and rationale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23903334" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : DSM-5 criteria for substance use disorders: recommendations and rationale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32487285" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Drug Overdose Deaths in the United States, 1999-2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32487285" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Drug Overdose Deaths in the United States, 1999-2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32487285" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Drug Overdose Deaths in the United States, 1999-2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27155756" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Nationwide increase in hospitalizations for heroin-related soft tissue infections: Associations with structural market conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32877563" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : National Public Health Burden Estimates of Endocarditis and Skin and Soft-Tissue Infections Related to Injection Drug Use: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34076676" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29913516" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28446428" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30615514" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32479224" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Buprenorphine Treatment By Primary Care Providers, Psychiatrists, Addiction Specialists, And Others.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20132117" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29435555" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Opioid Analgesic Use and Risk for Invasive Pneumococcal Diseases: A Nested Case-Control Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28501495" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28501495" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28501495" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12746360" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12746360" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18462109" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27537841" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30959528" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28237052" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Retention in buprenorphine treatment is associated with improved HCV care outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29778260" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27763996" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16988643" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16988643" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29879096" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Invasive Methicillin-Resistant Staphylococcus aureus Infections Among Persons Who Inject Drugs - Six Sites, 2005-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34823730" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Infectious Complications of Injection Drug Use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24281273" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24281273" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25413371" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Alcohol use disorders in opioid maintenance therapy: prevalence, clinical correlates and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12230968" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Current perspectives on smoking cessation among substance abusers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27816663" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Impact of quitting smoking and smoking cessation treatment on substance use outcomes: An updated and narrative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23617869" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Frequency and severity of comorbid mood and anxiety disorders in prescription opioid dependence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32022884" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24500948" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29396985" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Extended-release injectable naltrexone for opioid use disorder: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27265421" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Gabapentin misuse, abuse and diversion: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32271389" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Alcohol or Benzodiazepine Co-involvement With Opioid Overdose Deaths in the United States, 1999-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32271389" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Alcohol or Benzodiazepine Co-involvement With Opioid Overdose Deaths in the United States, 1999-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23953658" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12359036" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Smoking cessation in methadone maintenance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28857640" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Smoking Cessation Among Methadone-Maintained Patients: A Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24862167" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Varenicline efficacy and safety among methadone maintained smokers: a randomized placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28426439" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : High Mortality Among Patients With Opioid Use Disorder in a Large Healthcare System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22857878" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Polydrug abuse: a review of opioid and benzodiazepine combination use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24892008" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Managing Chronic Pain in Patients with Opioid Dependence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9006403" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Psychiatric and substance use comorbidity among treatment-seeking opioid abusers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18515693" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The prevalence of mental and physical health disorders among older methadone patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27416536" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Psychiatric comorbidities in opioid-dependent patients undergoing a replacement therapy programme in Spain: The PROTEUS study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19874168" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Psychiatric comorbidity reduces quality of life in chronic methadone maintained patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27434203" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Depression - A major but neglected consequence contributing to the health toll from prescription opioids?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27434203" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Depression - A major but neglected consequence contributing to the health toll from prescription opioids?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12963675" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17574803" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31829430" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Psychosocial interventions for people with both severe mental illness and substance misuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29065896" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Harm reduction principles for healthcare settings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27028542" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31058922" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Association Between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23372174" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28922449" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17697278" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31962347" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Effect of Needle Exchange Program on Maternal Hepatitis C Virus Prevalence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20513304" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : The effectiveness of harm reduction in preventing HIV among injecting drug users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16364566" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: Results from a community-based behavioral intervention trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28073688" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : State legal innovations to encourage naloxone dispensing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17215533" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Release from prison--a high risk of death for former inmates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16809167" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28399843" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Effectiveness of needle and syringe Programmes in people who inject drugs - An overview of systematic reviews.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12794555" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Needle exchange and injection drug use frequency: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24374889" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24374889" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25456324" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Supervised injection services: what has been demonstrated? A systematic literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25456324" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Supervised injection services: what has been demonstrated? A systematic literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26899802" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Estimating demand for primary care-based treatment for substance and alcohol use disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21170143" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Patients' Reasons for Choosing Office-based Buprenorphine: Preference for Patient-Centered Care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32078492" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32433364" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Low Barrier Tele-Buprenorphine in the Time of COVID-19: A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32893047" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33560696" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System's Initiative to Expand Treatment Access During the COVID-19 Pandemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34098299" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Low-barrier buprenorphine during the COVID-19 pandemic: A rapid transition to on-demand telemedicine with wide-ranging effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34098299" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Low-barrier buprenorphine during the COVID-19 pandemic: A rapid transition to on-demand telemedicine with wide-ranging effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22815062" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : They don't know what they don't know: internal medicine residents' knowledge and confidence in urine drug test interpretation for patients with chronic pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30122319" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30122319" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20187600" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Urine drug screening: a valuable office procedure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20924879" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Advanced urine toxicology testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28866369" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18445792" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Beyond abuse and exposure: framing the impact of prescription-medication sharing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18290581" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Use and misuse of buprenorphine in the management of opioid addiction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26305073" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Buprenorphine infrequently found in fatal overdose in New York City.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21844833" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25205666" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22704124" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30359928" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Understanding the use of diverted buprenorphine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24685458" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16870915" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12014814" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Treatment of heroin dependence with buprenorphine in primary care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21403039" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22065255" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23260506" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23734858" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Comparison of behavioral treatment conditions in buprenorphine maintenance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27978771" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25986647" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Buprenorphine Treatment and 12-step Meeting Attendance: Conflicts, Compatibilities, and Patient Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26662858" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31207453" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : A predictive risk model for nonfatal opioid overdose in a statewide population of buprenorphine patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
